Literature DB >> 26208456

Over-expression of TRIM37 promotes cell migration and metastasis in hepatocellular carcinoma by activating Wnt/β-catenin signaling.

Jianxin Jiang1, Chao Yu1, Meiyuan Chen1, She Tian1, Chengyi Sun2.   

Abstract

Hepatocellular carcinoma (HCC) is the most common cancer in the world especially in East Asia and Africa. Advanced stage, metastasis and frequent relapse are responsible for the poor prognosis of HCC. However, the precise mechanisms underlying HCC remained unclear. So it is urgent to identify the pathological processes and relevant molecules of HCC. TRIM37 is an E3 ligase and has been observed deregulated expression in various tumors. Recent studies of TRIM37 have implicated that TRIM37 played critical roles in cell proliferation and other processes. In the present study, we demonstrated that TRIM37 expression was notably up-regulated in HCC samples and was associated with advanced stage and tumor volume, which all indicating the poor outcomes. We also found that TRIM37 could serve as an independent prognostic factor of HCC. During the course of in vitro and in vivo work, we showed that TRIM37 promoted HCC cells migration and metastasis by inducing EMT. Furthermore, we revealed that the effect of TRIM37 mediated EMT in HCC cells was achieved by the activation of Wnt/β-catenin signaling. These finding may provide insight into the understanding of TRIM37 as a novel critical factor of HCC and a candidate target for HCC treatment.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma; Metastasis; Prognosis; TRIM37; β-catenin

Mesh:

Substances:

Year:  2015        PMID: 26208456     DOI: 10.1016/j.bbrc.2015.07.089

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  26 in total

1.  MicroRNA-2053 overexpression inhibits the development and progression of hepatocellular carcinoma.

Authors:  Tao Song; Ke Ma; Cui Zhao; Jijin Yang; Jingyu Liu
Journal:  Oncol Lett       Date:  2019-06-20       Impact factor: 2.967

2.  The essential role of MTDH in the progression of HCC: a study with immunohistochemistry, TCGA, meta-analysis and in vitro investigation.

Authors:  Rongquan He; Li Gao; Jie Ma; Zhigang Peng; Shengsheng Zhou; Lihua Yang; Zhenbo Feng; Yiwu Dang; Gang Chen
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

Review 3.  The roles of E3 ligases in Hepatocellular carcinoma.

Authors:  Zongdong Yu; Hong Li; Jie Zhu; Haibiao Wang; Xiaofeng Jin
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

Review 4.  TRIM37: a critical orchestrator of centrosome function.

Authors:  Andrés Domínguez-Calvo; Pierre Gönczy; Andrew J Holland; Fernando R Balestra
Journal:  Cell Cycle       Date:  2021-10-21       Impact factor: 5.173

5.  TRIM37 promotes epithelial‑mesenchymal transition in colorectal cancer.

Authors:  Cheng-En Hu; Jun Gan
Journal:  Mol Med Rep       Date:  2017-01-16       Impact factor: 2.952

6.  TIPE‑2 suppresses growth and aggressiveness of hepatocellular carcinoma cells through downregulation of the phosphoinositide 3‑kinase/AKT signaling pathway.

Authors:  Lin Wang; Chen Chen; Shuzhi Feng; Jianli Tian
Journal:  Mol Med Rep       Date:  2018-03-20       Impact factor: 2.952

7.  TRIM37 promotes tumor cell proliferation and drug resistance in pediatric osteosarcoma.

Authors:  Yanling Tao; Meiyun Xin; Huanchen Cheng; Zongxuan Huang; Tiantian Hu; Teng Zhang; Jianlong Wang
Journal:  Oncol Lett       Date:  2017-09-26       Impact factor: 2.967

8.  TRIM37 promotes cell invasion and metastasis by regulating SIP1-mediated epithelial-mesenchymal transition in gastric cancer.

Authors:  Dehu Chen; Xiaolan You; Yan Pan; Qinghong Liu; Gan Cao
Journal:  Onco Targets Ther       Date:  2018-12-10       Impact factor: 4.147

9.  MicroRNA-588 suppresses tumor cell migration and invasion by targeting GRN in lung squamous cell carcinoma.

Authors:  Li Qian; Longlong Lin; Yufeng Du; Xiaoyan Hao; Yuze Zhao; Xuejun Liu
Journal:  Mol Med Rep       Date:  2016-08-19       Impact factor: 2.952

10.  Combination therapy of hTERTR and FAM96A for hepatocellular carcinoma through enhancing apoptosis sensitivity.

Authors:  Wan-Peng Wang; Hai-Ying Gao
Journal:  Exp Ther Med       Date:  2017-11-13       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.